A clinical trial is exploring the combination of NOX-A12, a CXCL12 antagonist, with pembrolizumab in PDAC to enhance NK cell recruitment and improve immune responses by both directly targeting the tumor-promoting chemokine CXCL12 and releasing the brakes on the immune system. Here, CXCL12 is linked to neoplasm.